C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New Investment in McKesson Corporation $MCK

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in McKesson Corporation (NYSE:MCK) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,740 shares of the company’s stock, valued at approximately $1,428,000.

A number of other institutional investors have also recently made changes to their positions in the company. Alliancebernstein L.P. raised its holdings in McKesson by 150.4% in the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after acquiring an additional 1,362,386 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in McKesson by 45.6% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock valued at $610,977,000 after purchasing an additional 261,296 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of McKesson by 34.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 839,690 shares of the company’s stock worth $615,305,000 after purchasing an additional 213,406 shares in the last quarter. SurgoCap Partners LP increased its holdings in shares of McKesson by 68.7% in the 3rd quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock worth $349,390,000 after purchasing an additional 184,106 shares in the last quarter. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new position in shares of McKesson in the third quarter worth $135,352,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Stock Up 0.1%

NYSE:MCK opened at $885.42 on Friday. The business’s 50-day simple moving average is $912.57 and its two-hundred day simple moving average is $845.61. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The stock has a market cap of $108.45 billion, a PE ratio of 25.46, a P/E/G ratio of 1.26 and a beta of 0.42.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MCK shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. TD Cowen increased their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Wells Fargo & Company lifted their price target on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Finally, Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a research note on Sunday, March 22nd. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus price target of $960.93.

Insiders Place Their Bets

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michele Lau sold 2,725 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at $3,214,530. This trade represents a 45.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 3,868 shares of company stock worth $3,743,820. 0.08% of the stock is currently owned by company insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.